The Effect of Epiretinal Membrane on Dexamethasone Implant for Branch Retinal Vein Occlusion Macular Edema
10.3341/jkos.2019.60.9.843
- Author:
Mirinae JANG
1
;
Jin Young KIM
;
Sang Yoon LEE
;
Jin Ho JEONG
;
Eun Kyoung LEE
Author Information
1. Department of Ophthalmology, Jeju National University School of Medicine, Jeju, Korea. righthanded8282@gmail.com
- Publication Type:Original Article
- Keywords:
Branch retinal vein occlusion;
Epiretinal membrane;
Intravitreal dexamethasone implant;
Macular edema
- MeSH:
Dexamethasone;
Edema;
Epiretinal Membrane;
Humans;
Macular Edema;
Recurrence;
Retinal Vein Occlusion;
Retinal Vein;
Retinaldehyde;
Retreatment;
Retrospective Studies;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
2019;60(9):843-850
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the effect of epiretinal membrane (ERM) on the outcomes of intravitreal dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) treatment for macular edema (ME) secondary to branch retinal vein occlusion (BRVO). METHODS: Thirty eyes of 30 patients who received Ozurdex treatment for ME secondary to BRVO, and were followed-up for at least 6 months were retrospectively reviewed. Patients were divided into two groups based on the presence (ERM [+] or absence ERM [−]) of ERM at baseline. The best-corrected visual acuity (BCVA), central foveal thickness (CFT), recurrence of ME, and retreatment rate were evaluated at baseline, 1, 3, and 6 months after Ozurdex injection. RESULTS: Ten eyes of 30 eyes (33%) showed ERM at baseline. While the mean CFT was significantly reduced at 1 month after Ozurdex injection, it began to increase gradually thereafter in both groups. The ERM (+) group showed a significantly higher mean CFT than the corresponding values of the ERM (−) group at 1 (p = 0.022) and 6 months (p = 0.001) after Ozurdex injection. However, no significant difference was found in the BCVA between the two groups at every visit. The proportion of eyes with ME was significantly higher in the ERM (+) group (90%) than that in the ERM (−) group (35%) at 6 months after Ozurdex injection (p = 0.009). There were no significant differences between the two groups in the percentage of retreatment, time to retreatment, and type of materials used for retreatment. CONCLUSIONS: In patients with ME secondary to BRVO, the treatment effect of Ozurdex was low and the duration of treatment was short when ERM was concurrently present. However, the presence of ERM did not significantly affect visual outcomes after treatment with Ozurdex.
